Get the Stockscreener App
1.69
1.20%
0.02
After Hours:
1.68
-0.01
-0.59%
In 8 Bio Inc stock is traded at $1.69, with a volume of 53,922.
It is up +1.20% in the last 24 hours and up +12.67% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.67
Open:
$1.67
24h Volume:
53,922
Relative Volume:
0.86
Market Cap:
$16.64M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.6357
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
+16.55%
1M Performance:
+12.67%
6M Performance:
-15.92%
1Y Performance:
-61.12%
1-Day Range:
$1.65
$1.70
1-Week Range:
$1.425
$1.75
52-Week Range:
$1.17
$5.61
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.69 | 16.44M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Passage Bio, Inc. 2026 Annual Meeting Results: Stockholder Votes and Key Corporate Information (Form 8-K) - Minichart
Passage Bio (NASDAQ: PASG) holders choose annual say-on-pay at 2026 meeting - Stock Titan
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
VBIO SEC FilingsValion Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Annovis Bio (NYSE: ANVS) prices $15M common stock and warrant offering - Stock Titan
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options - Stock Titan
Debt exchange and FDA path shape Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan
Instil Bio, Inc. Reports First Quarter 2026 Financial Results – 8-K Filing Details and Key Highlights - Minichart
[SCHEDULE 13G/A] Adicet Bio, Inc. Amended Passive Investment Disclosure - Stock Titan
Instil Bio (Nasdaq: TIL) trims Q1 2026 loss and extends cash runway beyond 2027 - Stock Titan
Gossamer Bio, Inc.Common Stock (NQ: GOSS - FinancialContent
Valion Bio (VBIO) widens Q1 2026 loss as it builds TLR5 and CDMO platform - Stock Titan
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
IPF Phase 2a results and cash runway update for GRI Bio (NASDAQ: GRI) - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan
Cabaletta Bio (NASDAQ: CABA) unveils new rese-cel autoimmune and PC-free data - Stock Titan
Adicet Bio (Nasdaq: ACET) trims Q1 loss and details prula-cel, ADI-212 plans - Stock Titan
Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108 - Stock Titan
TELA Bio (NASDAQ: TELA) Q1 2026 revenue rises 3% to $19.1M - Stock Titan
TELA Bio rolls out fully resorbable hernia repair after $19M Q1 - Stock Titan
Kyntra Bio (NASDAQ: FGEN) Q1 2026 results, oncology pipeline and cash runway - Stock Titan
Avai Bio (NASDAQ: AVAI) and Ainnova mutually end AI healthcare joint venture - Stock Titan
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
QTTB SEC FilingsQ32 BIO INC 10-K, 10-Q, 8-K Forms - Stock Titan
Boundless Bio (Nasdaq: BOLD) Q1 2026 results and $92.8M cash runway - Stock Titan
Kala Bio (NASDAQ: KALA) sets 1-for-50 reverse stock split, May 11 start - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
BLTE SEC FilingsBelite Bio, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ImmunityBio (NASDAQ: IBRX) boosts Q1 sales but records $632.8M loss - Stock Titan
[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing - Stock Titan
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences - GlobeNewswire Inc.
INmune Bio (NASDAQ: INMB) deepens Anthony Nolan CORDStrom supply pact - Stock Titan
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Q32 Bio (QTTB) narrows Q1 2026 loss and funds runway into 1H 2028 - Stock Titan
Valion Bio (Nasdaq: VBIO) hires Melinda Lackey as General Counsel - Stock Titan
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Cabaletta Bio (NASDAQ: CABA) prices $150M equity raise to fund rese-cel - Stock Titan
Cabaletta Bio (NASDAQ: CABA) to share new rese-cel RESET-PV data at ASGCT 2026 - Stock Titan
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] TELA Bio, Inc. SEC Filing - Stock Titan
Leadership shake-up at TELA Bio (NASDAQ: TELA) as new chair named - Stock Titan
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th - The Manila Times
Valion Bio, Inc. Common Stock (VBIO) 10K Form and Latest SEC Filings 2026 - MarketBeat
[ARS] Boundless Bio, Inc. SEC Filing - Stock Titan
Adicet Bio (NASDAQ: ACET) issues 250,000-share pre-funded warrant in exchange deal - Stock Titan
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
BIO-key International, Inc. Files 8-K Report on Security Holder Vote Results – April 2026 - Minichart
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):